Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in breast, colon and prostate cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.
Drew Watson currently serves as Senior Vice President of Biostatistics, Data Management, and Medical Operations. Drew joined Genomic Health in 2003 and was instrumental in the development of Oncotype DX® tests for Breast, Colon and Prostate Cancer. Oncotype DX® for Breast Cancer is a clinically-validated diagnostic test that is recommended in NCCN guidelines and has revolutionized personal medicine by quantifying the likelihood of disease recurrence in women with early-stage breast cancer and providing individualized estimates of chemotherapy benefit.
For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit:
www.OncotypeDX.com
www.mybreastcancertreatment.org
www.myprostatecancertreatment.org.